Sonia Quaratino

Dr. Quaratino has over 25 years of experience in immunology research, clinical development at biotechnology and pharmaceutical companies, has served on multiple boards, and overseen research programs at leading academic institutions. Her scientific interest includes the understanding of pathogenic mechanisms underlying chronic inflammatory diseases and the interface between autoimmunity and cancer.

She is currently Chief Medical Officer at Georgiamune INC (USA), Chair of the Scientific and Clinical Advisory Board for STipe Therapeutics and a non-executive director for Circio ASA (OSE: CRNA) (previously known as TargoVax) and Ichnos Sciences INC.

Prior to her transition to a portfolio career, Dr Quaratino was Chief Medical Officer for Kymab, a clinical-stage biopharmaceutical company with a focus on immune-mediated diseases and immuno-oncology therapeutics, acquired by Sanofi for more than $1.1 billion in April 2021. Previously, she held roles as Global Clinical Program Leader in Translational Clinical Oncology at Novartis, Senior Medical Director and Immunology Advisor at Merck Serono, and was Professor of Immunology at the University of Southampton.

Dr. Quaratino received her Medical Degree and Doctorate in Hematology-Oncology from the University of Palermo, and her Ph.D. in Immunology from Imperial College London.